Evidence map›Paper›PMID 35296366›Full record

ArticleActa neuropathologica communications2022

Microglia phenotypes are associated with subregional patterns of concomitant tau, amyloid-β and α-synuclein pathologies in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies.

Sonja Fixemer, Corrado Ameli, Gaël Hammer, Luis Salamanca, Oihane Uriarte Huarte, Chantal Schwartz, Jean-Jacques Gérardy, Naguib Mechawar, Alexander Skupin, Michel Mittelbronn and 1 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Fibrin-Targeting Immunotherapy for Dementia.The journal of prevention of Alzheimer's disease · 2023
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Sonja Fixemer *Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belval, Luxembourg.
Corrado Ameli *Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belval, Luxembourg.
Gaël HammerLuxembourg Center of Neuropathology (LCNP), Dudelange, Luxembourg.
Luis SalamancaLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belval, Luxembourg.
Oihane Uriarte HuarteLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belval, Luxembourg.
Chantal SchwartzLaboratoire National de Santé (LNS), National Center of Pathology (NCP), Dudelange, Luxembourg.
Jean-Jacques GérardyLuxembourg Center of Neuropathology (LCNP), Dudelange, Luxembourg.
Naguib MechawarDepartment of Psychiatry, Douglas Mental Health University Institute, McGill University, Montreal, QC, Canada.
Alexander SkupinLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belval, Luxembourg.
Michel MittelbronnLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belval, Luxembourg.
David S BouvierLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belval, Luxembourg. David.Bouvier@lns.etat.lu.ORCID 0000-0002-8630-1044
University of Luxembourg · LULaboratoire National de Santé · LUDouglas Mental Health University Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cellular alterations of the hippocampus lead to memory decline, a shared symptom between Alzheimer's disease (AD) and dementia with Lewy Bodies (DLB) patients. However, the subregional deterioration pattern of the hippocampus differs between AD and DLB with the CA1 subfield being more severely affected in AD. The activation of microglia, the brain immune cells, could play a role in its selective volume loss. How subregional microglia populations vary within AD or DLB and across these conditions remains poorly understood. Furthermore, how the nature of the hippocampal local pathological imprint is associated with microglia responses needs to be elucidated. To this purpose, we employed an automated pipeline for analysis of 3D confocal microscopy images to assess CA1, CA3 and DG/CA4 subfields microglia responses in post-mortem hippocampal samples from late-onset AD (n = 10), DLB (n = 8) and age-matched control (CTL) (n = 11) individuals. In parallel, we performed volumetric analyses of hyperphosphorylated tau (pTau), amyloid-β (Aβ) and phosphorylated α-synuclein (pSyn) loads. For each of the 32,447 extracted microglia, 16 morphological features were measured to classify them into seven distinct morphological clusters. Our results show similar alterations of microglial morphological features and clusters in AD and DLB, but with more prominent changes in AD. We identified two distinct microglia clusters enriched in disease conditions and particularly increased in CA1 and DG/CA4 of AD and CA3 of DLB. Our study confirms frequent concomitance of pTau, Aβ and pSyn loads across AD and DLB but reveals a specific subregional pattern for each type of pathology, along with a generally increased severity in AD. Furthermore, pTau and pSyn loads were highly correlated across subregions and conditions. We uncovered tight associations between microglial changes and the subfield pathological imprint. Our findings suggest that combinations and severity of subregional pTau, Aβ and pSyn pathologies transform local microglia phenotypic composition in the hippocampus. The high burdens of pTau and pSyn associated with increased microglial alterations could be a factor in CA1 vulnerability in AD.

Indexed as

Alzheimer DiseaseLewy Body Diseasealpha-SynucleinAmyloid beta-PeptidesHippocampusHumansMicrogliaPhenotypetau Proteinsalpha-SynucleinAmyloid beta-Peptidestau ProteinsAlzheimer’s diseaseAmyloid-βDementia with Lewy BodiesHippocampusHyperphosphorylated tauMicrogliaPhosphorylated α-synuclein

Identifiers

PMID35296366
PMCPMC8925098
OpenAlexW4220740208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.